DexCom, Inc. (NASDAQ:DXCM) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have received a consensus rating of “Moderate Buy” from the twenty-five analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, seventeen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $85.1818.

A number of research firms have recently issued reports on DXCM. Leerink Partners restated an “outperform” rating and issued a $92.00 price target on shares of DexCom in a research note on Tuesday, December 16th. Barclays reiterated an “underweight” rating and set a $72.00 price objective (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Robert W. Baird set a $87.00 target price on DexCom in a report on Friday, February 13th. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. Finally, Canaccord Genuity Group set a $95.00 price target on DexCom and gave the company a “buy” rating in a research note on Friday, February 13th.

DexCom Stock Down 3.7%

Shares of DexCom stock opened at $68.10 on Monday. The company has a market cap of $26.21 billion, a price-to-earnings ratio of 32.43, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. The company’s 50 day moving average is $70.69 and its 200 day moving average is $68.75. DexCom has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm’s revenue was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.45 EPS. Research analysts anticipate that DexCom will post 2.03 EPS for the current year.

Institutional Trading of DexCom

Several large investors have recently added to or reduced their stakes in DXCM. Trust Co. of Vermont raised its position in DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after acquiring an additional 145 shares during the period. CVA Family Office LLC grew its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the period. GAMMA Investing LLC increased its stake in shares of DexCom by 2.5% in the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after purchasing an additional 169 shares in the last quarter. IFP Advisors Inc increased its stake in shares of DexCom by 24.7% in the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after purchasing an additional 178 shares in the last quarter. Finally, Inspire Investing LLC raised its holdings in DexCom by 6.1% in the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after purchasing an additional 180 shares during the period. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.